PURPOSE: Nonsteroidal anti-inflammatory drugs (NSAIDs) target the prostaglandin H synthase enzymes, cyclooxygenase (COX)-1 and COX-2, and reduce colorectal cancer risk. Genetic variation in the genes encoding these enzymes may be associated with changes in colon and rectal cancer risk and in NSAID efficacy. METHODS: We genotyped candidate polymorphisms and tag SNPs in PTGS1 (COX-1) and PTGS2 (COX-2) in a population-based case–control study (Diet, Activity and Lifestyle Study, DALS) of colon cancer (n = 1,470 cases/1,837 controls) and rectal cancer (n = 583/775), and independently among cases and controls from the Colon Cancer Family Registry (CCFR; colon n = 959/1,535, rectal n = 505/839). RESULTS: In PTGS2, a functional polymorphism (-765G[C; rs20417) was associated with a twofold increased rectal cancer risk (p = 0.05) in the DALS. This association replicated with a significant nearly fivefold increased risk of rectal cancer in the CCFR study (ORCC vs. GG = 4.88; 95 % CI 1.54–15.45; ORGC vs. GG = 1.36; 95 %CI 0.95–1.94). Genotype–NSAID interactions were observed in the DALS for PTGS1 and rectal cancer risk and for PTGS2 and colon cancer risk, but were no longer significant after correcting for multiple comparisons and did not replicate in the CCFR. No significant associations between PTGS1 polymorphisms and colon or rectal cancer risk were observed.
PURPOSE: Nonsteroidal anti-inflammatory drugs (NSAIDs) target the prostaglandin H synthase enzymes, cyclooxygenase (COX)-1 and COX-2, and reduce colorectal cancer risk. Genetic variation in the genes encoding these enzymes may be associated with changes in colon and rectal cancer risk and in NSAID efficacy. METHODS: We genotyped candidate polymorphisms and tag SNPs in PTGS1 (COX-1) and PTGS2 (COX-2) in a population-based case–control study (Diet, Activity and Lifestyle Study, DALS) of colon cancer (n = 1,470 cases/1,837 controls) and rectal cancer (n = 583/775), and independently among cases and controls from the Colon Cancer Family Registry (CCFR; colon n = 959/1,535, rectal n = 505/839). RESULTS: In PTGS2, a functional polymorphism (-765G[C; rs20417) was associated with a twofold increased rectal cancer risk (p = 0.05) in the DALS. This association replicated with a significant nearly fivefold increased risk of rectal cancer in the CCFR study (ORCC vs. GG = 4.88; 95 % CI 1.54–15.45; ORGC vs. GG = 1.36; 95 %CI 0.95–1.94). Genotype–NSAID interactions were observed in the DALS for PTGS1 and rectal cancer risk and for PTGS2 and colon cancer risk, but were no longer significant after correcting for multiple comparisons and did not replicate in the CCFR. No significant associations between PTGS1 polymorphisms and colon or rectal cancer risk were observed.
Authors: Elizabeth M Poole; Jeannette Bigler; John Whitton; Justin G Sibert; Richard J Kulmacz; John D Potter; Cornelia M Ulrich Journal: Carcinogenesis Date: 2007-02-02 Impact factor: 4.944
Authors: Cornelia M Ulrich; Jeannette Bigler; Justin Sibert; Elizabeth A Greene; Rachel Sparks; Christopher S Carlson; John D Potter Journal: Hum Mutat Date: 2002-11 Impact factor: 4.878
Authors: Craig R Lee; Frank G Bottone; Joseph M Krahn; Leping Li; Harvey W Mohrenweiser; Molly E Cook; Robert M Petrovich; Douglas A Bell; Thomas E Eling; Darryl C Zeldin Journal: Pharmacogenet Genomics Date: 2007-02 Impact factor: 2.089
Authors: Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-11-02 Impact factor: 4.254
Authors: Daniel Iglesias; Nargisse Nejda; Mariano Moreno Azcoita; Simó Schwartz; Juan J González-Aguilera; Antonia M Fernández-Peralta Journal: Cancer Causes Control Date: 2009-05-27 Impact factor: 2.506
Authors: Hongmei Nan; Carolyn M Hutter; Yi Lin; Eric J Jacobs; Cornelia M Ulrich; Emily White; John A Baron; Sonja I Berndt; Hermann Brenner; Katja Butterbach; Bette J Caan; Peter T Campbell; Christopher S Carlson; Graham Casey; Jenny Chang-Claude; Stephen J Chanock; Michelle Cotterchio; David Duggan; Jane C Figueiredo; Charles S Fuchs; Edward L Giovannucci; Jian Gong; Robert W Haile; Tabitha A Harrison; Richard B Hayes; Michael Hoffmeister; John L Hopper; Thomas J Hudson; Mark A Jenkins; Shuo Jiao; Noralane M Lindor; Mathieu Lemire; Loic Le Marchand; Polly A Newcomb; Shuji Ogino; Bethann M Pflugeisen; John D Potter; Conghui Qu; Stephanie A Rosse; Anja Rudolph; Robert E Schoen; Fredrick R Schumacher; Daniela Seminara; Martha L Slattery; Stephen N Thibodeau; Fridtjof Thomas; Mark Thornquist; Greg S Warnick; Brent W Zanke; W James Gauderman; Ulrike Peters; Li Hsu; Andrew T Chan Journal: JAMA Date: 2015-03-17 Impact factor: 56.272
Authors: Elena M Stoffel; Pamela B Mangu; Stephen B Gruber; Stanley R Hamilton; Matthew F Kalady; Michelle Wan Yee Lau; Karen H Lu; Nancy Roach; Paul J Limburg Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Elizabeth D Kantor; Ruzan Udumyan; Lisa B Signorello; Edward L Giovannucci; Scott Montgomery; Katja Fall Journal: Gut Date: 2015-05-18 Impact factor: 23.059
Authors: Harsh Sheth; Emma Northwood; Cornelia M Ulrich; Dominique Scherer; Faye Elliott; Jennifer H Barrett; David Forman; C Roland Wolf; Gillian Smith; Michael S Jackson; Mauro Santibanez-Koref; Robert Haile; Graham Casey; Mark Jenkins; Aung Ko Win; John L Hopper; Loic Le Marchand; Noralane M Lindor; Stephen N Thibodeau; John D Potter; John Burn; D Timothy Bishop Journal: PLoS One Date: 2018-02-09 Impact factor: 3.240